Oregon Clinical and Translational Research Institute
Oregon Clinical and Translational Research Institute
批准号:
10693308
负责人:
David H Ellison
金额:
$967.3万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-09-02 至 2027-07-31
中文摘要
总体-项目摘要
俄勒冈州临床和转化研究所(OCTRI)是一个成熟的CTSA中心,
自2006年以来,俄勒冈州健康与科学大学(OHSU)一直在加速研究。它有一个稳定,但灵活,
在本供资周期内有效运作以实现其目标的领导结构。OCTRI
受益于若干咨询小组在评价和规划方面的指导,并将利用它们的投入,
不断改善结构。OCTRI的许多有效的计划帮助调查人员和学员,
提供支持服务和促进新的方法,以改善健康在俄勒冈州和超越。OCTRI
现在将在这些优势的基础上,同时扩大其影响范围,以实现与国家目标相一致的目标。
这一战略旨在加强NCATS所阐述的优先事项,并巩固其在CTSA网络中的作用。OCTRI在全国范围内发展
公认的计划,以建立翻译劳动力,并将加强这一基础,带来更多的多样性,
同时也确保严格的能力得到满足。OCTRI已建立了领先的区域声誉
创新,并已将这些资产纳入奈特癌症研究所的可选功能,
支持新疗法的发展。OCTRI在整个农村地区建立了信任和研究能力
俄勒冈州,现在将把这些努力扩大到波特兰大都市地区。OCTRI的当前可选功能
在研究中放大了患者的声音,现在它将被整合到社区计划中,
扩展其范围。OCTRI在国家信息学平台的开发方面处于领先地位,现在将利用
那些建立整个OHSU的内部支持流程,使这些资源民主化。与此同时,
OCTRI已认识到数据共享方面的局限性,并将开发一种新的可选功能,
整合快速医疗保健互操作性资源,将健康的社会决定因素转化为
电子系统。该研究所一直处于创新成果评价的前沿,并将全面实施
转化科学效益模型。这些目标将通过让不同的利益攸关方参与来实现,
通过与OHSU调查人员,社区联盟和商业企业合作,并通过培养团队
科学通过这些努力,OCTRI将成为OHSU,俄勒冈州和
民族
英文摘要
Overall - Project Summary
The Oregon Clinical and Translational Research Institute (OCTRI) is a mature CTSA hub that has been
accelerating research at Oregon Health & Science University (OHSU) since 2006. It has a stable, yet nimble,
leadership structure that has functioned efficiently during the current funding cycle to meet its goals. OCTRI
benefits from the guidance of several advisory groups in evaluation and planning and will use their input to
continuously improve its structure. OCTRI’s many effective programs assist investigators and trainees by
providing support services and fostering novel approaches to improve health in Oregon and beyond. OCTRI
will now build on these strengths, while broadening its reach, to address goals that align with the national
priorities articulated by NCATS and solidify its role within the CTSA network. OCTRI has developed nationally
recognized programs to build the translational workforce, and will strengthen this base to bring more diversity,
while also ensuring rigorous competencies are met. OCTRI has developed a regional reputation for leading
innovation and have incorporated these assets in an optional function with the Knight Cancer Institute that
supports the development of new therapeutics. OCTRI has built trust and capacity in research throughout rural
Oregon and will now extend these efforts to the Portland metropolitan region. OCTRI’s current optional function
has amplified the patient voice in research, and it will now be integrated into the community program in order to
extend its reach. OCTRI has led in the development of national informatics platforms and will now leverage
those to build internal support processes throughout OHSU to democratize these resources. At the same time,
OCTRI has recognized limitations with regard to data sharing and will develop a novel optional function to
incorporate Fast Healthcare Interoperability Resources to translate social determinants of health across
electronic systems. OCTRI has been at the forefront of innovative outcome evaluation and will fully implement
the Translational Science Benefits Model. These goals will be accomplished by engaging diverse stakeholders,
by partnering with OHSU investigators, community coalitions, and business enterprises, and by fostering team
science. Through these efforts, OCTRI will become even more essential for OHSU, for Oregon, and for the
nation.
期刊论文(319)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/jbmr.4619
发表时间:
2022-08
期刊:
JOURNAL OF BONE AND MINERAL RESEARCH
影响因子:
6.2
作者:
[Alajlouni, Dima A., Bliuc, Dana, Tran, Thach S., Blank, Robert D., Cawthon, Peggy M., Ensrud, Kristine E., Lane, Nancy E., Orwoll, Eric S., Cauley, Jane A., Center, Jacqueline R.]
通讯作者:
Center, Jacqueline R.
DOI:
10.1002/onco.13674
发表时间:
2021-04
期刊:
The oncologist
影响因子:
--
作者:
[George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M]
通讯作者:
von Mehren M
DOI:
10.1111/jocn.16511
发表时间:
2023-07
期刊:
JOURNAL OF CLINICAL NURSING
影响因子:
4.2
作者:
[Christensen, Vivian, Parker, Kellee, Chan, Lai Hin Kimi, Saxton, Lauren, Cottrell, Erika]
通讯作者:
Cottrell, Erika
DOI:
10.3389/fendo.2021.651211
发表时间:
2021
期刊:
Frontiers in endocrinology
影响因子:
5.2
作者:
[Ehrlicher SE, Stierwalt HD, Newsom SA, Robinson MM]
通讯作者:
Robinson MM
DOI:
10.1016/j.bios.2020.112221
发表时间:
2020-10-01
期刊:
Biosensors & bioelectronics
影响因子:
12.6
作者:
[]
通讯作者:
共 183 条
Core-003
-
批准号:10198072
-
项目类别:
-
资助金额:$93.68万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Admin-Core-001
-
批准号:10198069
-
项目类别:
-
资助金额:$90.49万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute Quality Assurance and Quality Control Project
-
批准号:10158949
-
项目类别:
-
资助金额:$14.93万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute
-
批准号:10198068
-
项目类别:
-
资助金额:$630.8万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Core-005
-
批准号:10198074
-
项目类别:
-
资助金额:$164.5万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)
-
批准号:10179888
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute
-
批准号:9514362
-
项目类别:
-
资助金额:$616.99万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Core-001
-
批准号:10198070
-
项目类别:
-
资助金额:$68.71万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Core-002
-
批准号:10198071
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute - Evaluation of OCTRI's Response to COVID-19
-
批准号:10158990
-
项目类别:
-
资助金额:$9.35万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute
-
批准号:10675189
-
项目类别:
-
资助金额:$967.3万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Core-007
-
批准号:10198076
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Core-006
-
批准号:10198075
-
项目类别:
-
资助金额:$65.22万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Core-004
-
批准号:10198073
-
项目类别:
-
资助金额:$70.08万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute
-
批准号:9977301
-
项目类别:
-
资助金额:$633.75万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Oregon Clinical and Translational Research Institute
-
批准号:9816556
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2017
-
负责人:David H Ellison
-
依托单位:
Renal Effects of Aldosterone
-
批准号:10266000
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:David H Ellison
-
依托单位:
Renal and extrarenal toxicity of aldosterone
-
批准号:9280815
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:David H Ellison
-
依托单位:
Renal and extrarenal toxicity of aldosterone
-
批准号:8635009
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:David H Ellison
-
依托单位:
Molecular pathogenesis of calcineurin inhibitor-induced hypertension
-
批准号:8549218
-
项目类别:
-
资助金额:$35.68万
-
财政年份:2012
-
负责人:David H Ellison
-
依托单位:
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
-
批准号:31070748
-
项目类别:面上项目
-
资助金额:34.0万元
-
批准年份:2010
-
负责人:Christine Nardini
-
依托单位: